GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...
Micron hits record AI-driven revenue, but peak-cycle pricing, rich valuation, and $20B FY2026 CapEx raise oversupply risk.
Department of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, United States ...
SUGAR LAND, Texas--(BUSINESS WIRE)--Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to ...
Micron posted 257% year-over-year earnings growth as memory pricing recovered. SOXL holds roughly 30% in cash and treasury instruments to enable daily rebalancing. This creates drag during rallies.
A host of other issues are driving yields higher as well; if inflation was really 'over', borrowing costs would be much lower, one investor says Treasury yields are rising alongside their counterparts ...
Capricor Therapeutics has notched a key win in its efforts to bring its Duchenne muscular dystrophy cell therapy, deramiocel, to market, hitting the primary endpoint in a phase 3 trial. In 105 boys ...
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Positive, early results ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Between Aug 31, 2022, and ...
Rajeev Dhir is a writer with 10+ years of experience as a journalist with a background in broadcast, print, and digital newsrooms. Betsy began her career in international finance and it has since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback